A5083431383- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Cutaneous Melanoma Detection and Management
- Brain Metastases and Treatment
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Microscopic Colitis
- Neuroendocrine Tumor Research Advances
- Health Systems, Economic Evaluations, Quality of Life
- Cytokine Signaling Pathways and Interactions
- COVID-19 and healthcare impacts
- HER2/EGFR in Cancer Research
- Medical Imaging and Pathology Studies
- Neutropenia and Cancer Infections
- Drug-Induced Adverse Reactions
- Glioma Diagnosis and Treatment
Harvard University
2017-2025
Massachusetts General Hospital
2017-2025
John Wiley & Sons (United States)
2020
Hudson Institute
2020
Global Cancer Institute
2017-2019
Brigham and Women's Hospital
2019
Mayo Clinic
2019
Mayo Clinic in Arizona
2019
Dana-Farber Cancer Institute
2011-2017
University of Arkansas for Medical Sciences
2017
Lung cancer is made up of distinct subtypes, including non-small-cell lung (NSCLC) and small-cell (SCLC). Although overall mortality from has been declining in the United States, little known about trends according to subtype at population level because death certificates do not record information.Using data Surveillance, Epidemiology, End Results (SEER) areas, we assessed lung-cancer linked deaths incident cases SEER registries. This allowed us evaluate population-level attributed specific...
Background and objectives Immune checkpoint inhibitor use in oncology is increasing rapidly. We sought to determine the frequency, severity, cause, predictors of AKI a real-world population receiving inhibitors. Design, setting, participants, & measurements included all patients who received therapy from May 2011 December 2016 at Massachusetts General Hospital. Baseline serum creatinine, averaged 6 months before start date, was compared with subsequent creatinine values within 12...
Expanding use of immune-checkpoint inhibitors (ICIs) underscores the importance accurate diagnosis and timely management neurological immune-related adverse events (irAE-N). We evaluate real-world frequency, phenotypes, co-occurring (irAEs), long-term outcomes severe, grade III to V irAE-N at a tertiary care center over 6 years. analyze how our experience supports published literature professional society guidelines. also discuss these data with regard common clinical scenarios, such as...
Expanding the US Food and Drug Administration-approved indications for immune checkpoint inhibitors in patients with cancer has resulted therapeutic success immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%-12% a high fatality rate relative to other irAEs. Lack standardized disease definitions accurate phenotyping leads syndrome misclassification impedes development evidence-based treatments translational research. The objective this study was develop...
<h3>Objective</h3> To describe the spectrum, clinical course, and management of neuropathies associated with immune checkpoint inhibitors (ICIs). <h3>Methods</h3> Patients ICI-related neuropathy (irNeuropathy) were identified their characteristics compared to attributed cytotoxic agents. <h3>Results</h3> We 19 patients irNeuropathies. ICIs included anti-programmed death–1 (PD1), 9; anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), 2; combination anti-CTLA4 anti-PD1, 8. Median number...
Immune checkpoint inhibitors (ICIs) are standard therapies for patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. Tumor mutation burden (TMB) also predicts response to ICIs but is often not available in real time decision making the first-line setting. Smoking exposure can be proxy TMB NSCLC. The impact of smoking status on efficacy PD-1 blockade NSCLC PD-L1 TPS ≥50% has been well defined.To investigate...
Background Immune checkpoint inhibitors (ICIs) have improved survival and are increasingly used for non-small cell lung cancer. However, use may be limited by immune-related adverse events such as checkpoint-inhibitor pneumonitis (CIP). Literature estimates CIP incidence inconsistent. Real-world adherence to guidelines, clinical course, healthcare utilization in the treatment of has not been described large cohorts. Methods A combined claims electronic health record database (TriNetX) was...
Acral melanoma is a rare subtype with poor prognosis. Importantly, these patients were not identified as specific subgroup in the landmark trials involving ipilimumab and anti-programmed cell death protein-1 (PD-1) agents nivolumab pembrolizumab. There therefore an absence of prospective clinical trial evidence regarding efficacy checkpoint inhibitors (CPIs) this population. has lower tumor mutation burden (TMB) than other cutaneous sites, primary site associated differences TMB. However...
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) CTLA4 inhibitors and PD-1 or PD-L1 (hereafter, PD-(L)1 inhibitors) is associated higher rates of anti-tumour activity immune-related toxicities, when compared treatment alone. However, there are currently no validated biomarkers to identify which will benefit from ICB1,2. Here we show that NSCLC who have mutations in the STK11 and/or KEAP1 tumour suppressor genes derived clinical ICB...
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence immune-related adverse events (irAEs) is on rise. Dermatologic (D-irAEs) are most common and earliest to manifest, often with important downstream consequences patient. Current guidelines lack clarity in terms diagnostic criteria D-irAEs. The goal this project better define D-irAE purposes identification, diagnosis, future study group diseases.The objectives were develop consensus guidance approach...
PURPOSE Current approaches to accurately identify immune-related adverse events (irAEs) in large retrospective studies are limited. Large language models (LLMs) offer a potential solution this challenge, given their high performance natural comprehension tasks. Therefore, we investigated the use of an LLM irAEs among hospitalized patients, comparing its with manual adjudication and International Classification Disease (ICD) codes. METHODS Hospital admissions patients receiving immune...
The use of immune checkpoint inhibitors (ICIs) is increasing. Little known about the frequency late-onset immune-related adverse events (irAEs) and patient-specific risk factors associated with their development. To assess incidence persistent or de novo irAEs requiring hospitalization identify patient irAEs. This retrospective observational cohort study conducted from January 2011 to October 2022 included patients who received ICIs were hospitalized at an academic medical center. Exclusion...
Most metastatic melanoma patients treated with BRAF inhibitors (BRAFi) ± MEK (MEKi) eventually progress on treatment. Along acquired resistance due to genetic changes, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was analyse retrospectively outcomes for retreated BRAF-directed therapy.One hundred sixteen who received BRAFi-based therapy and, a break, were rechallenged MEKi at 14 centres in Europe, US and Australia...
<h3>Importance</h3> Immune checkpoint inhibitor combination therapy has recently become the standard of care for first-line treatment metastatic nonsquamous non–small cell lung cancer. The implications these treatments are considerable, given potential population patients eligible to receive them and their high cost. <h3>Objective</h3> To evaluate cost-effectiveness adding atezolizumab bevacizumab, carboplatin, paclitaxel as a strategy with cancer in United States. <h3>Design, Setting,...
Immune-related colitis is a common, often serious complication of immune checkpoint inhibition (ICI). Although endoscopy not strictly recommended for any grade diarrhea/colitis, emerging evidence suggests that endoscopic evaluation may have important therapeutic implications. In this retrospective study, we sought to comprehensively characterize the clinical and histologic features ICI-induced with specific focus on evaluating prognostic role endoscopy.Data were collected from medical...
<h3>Importance</h3> In early 2018, durvalumab became the first immunotherapy to be approved for adjuvant treatment of patients with unresectable stage III non–small cell lung cancer (NSCLC) whose has not progressed after definitive chemoradiotherapy. However, cost-effectiveness and potential economic implications using this high-priced therapy in indication are unknown date. <h3>Objective</h3> To explore budgetary consequences consolidation vs no chemoradiotherapy NSCLC context US health...
Background Rare cases of immune checkpoint inhibitor (ICI)-associated celiac disease (ICI-CeD) have been reported, suggesting that disruption tolerance mechanisms by ICIs can unmask (CeD). This study aims to characterize the clinicopathological and immunophenotypic features ICI-CeD in comparison ICI-associated duodenitis (ICI-Duo) usual CeD. Methods A medical pathological records search between 2015 2019 identified eight ICI-CeD, confirmed tTG-IgA. Nine ICI-Duo, 28 moderate CeD, as well 5...
Immune checkpoint inhibitors (ICI) predispose patients to immune-related adverse events (irAEs). Although hepatitis is a potentially lethal toxicity, the timing and outcomes have not been well described. In this retrospective study, from six international institutions were included if they treated with ICIs developed hepatitis. Patient tumor characteristics, management evaluated. Of 164 included, most male (53.7%) median age of 63.0 years. Most had melanoma (83.5%) stage IV disease (86.0%)....
Immune checkpoint inhibitors (ICIs) are approved to treat multiple cancers. Retrospective analyses demonstrate acceptable safety of ICIs in most patients with autoimmune disease, although disease exacerbation may occur. Psoriasis vulgaris is a common, immune-mediated and outcomes ICI treatment psoriasis not well described. Thus we sought define the profile effectiveness pre-existing psoriasis.In this retrospective cohort study, from eight academic centers who received for cancer were...
Since the first approval for immune checkpoint inhibitors (ICIs) treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed landscape this chemotherapy-resistant disease. Combination regimens including ICIs directed against programmed cell death protein 1 (PD-1) with anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) agents or, recently, anti-lymphocyte-activation gene 3 (LAG-3) agents, have gained regulatory approvals metastatic melanoma, long-term...
Colitis is a frequent, clinically-significant immune-related adverse event caused by anti-programmed death-1 (PD-1). The clinical features, timing, and management of colitis with anti-PD-1-based regimens are not well-characterized. Patients advanced melanoma that received either anti-PD-1 monotherapy ("monotherapy") or combined ipilimumab ("combination therapy") were screened from 8 academic medical centers, to identify those clinically-relevant (colitis requiring systemic steroids). Of 1261...
9020 Background: Osimertinib (osi) is an EGFR T790M inhibitor. Mechanisms (mech) of acquired resistance (AR) are under study. We report a cohort osi-AR pts with extensive pre/post-osi tissue and plasma. Methods: analyzed 23 AR to osi. Tumor biopsies (bx) underwent NGS (SNaPshot, MGH) FISH for EGFR, MET amp (target:CEP7 > 2.2.) Plasma ctDNA (Guardant360). Results: Of the osi-treated EGFR-mutants (13 del19, 10 L858R), 2 had de novo T790M, 21 T790M. 13 prior 3 rd gen TKIs before osi -...